|
Market Closed -
Nasdaq
16:00:00 2026-10-01 EDT
|
5-day change | 1st Jan Change | ||
| 8.210 USD | -4.09% |
|
+10.35% | +96.41% |
| 09-21 | Precigen Receives Fda Platform Technology Designation for Adenoverse Platform | CI |
| 09-21 | Precigen's AdenoVerse Receives FDA Platform Technology Designation | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Other Pharmaceuticals
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 3.06B | - | - | |||
| 1,031B | |||||
| 638B | - | ||||
| 462B | |||||
| 359B | |||||
| 335B |
- Stock Market
- Stocks
- PGEN Stock
- Charts Precigen, Inc.
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
